SELLAS Life Sciences Group, Inc.
Report topline data from the GPS investigator-sponsored trial in malignant pleural mesothelioma
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 May 2023
- Due
- 30 Jun 2023
- Delivered
- June 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“SELLAS expects to report topline data during the first half of 2023.”
What we found
Evidence strength A What the grades mean
The company reported in June 2023 that the primary endpoint of safety and the efficacy endpoint were met for the investigator-sponsored trial in malignant pleural mesothelioma.
-
A SELLAS Life Sciences Group, Inc. 10-Q filed 2023-08-10
“In June 2023, we reported that the primary endpoint of safety and the efficacy endpoint were both met with clinical activity and increased survival in this study.” ✓ confirmed on the page
Market reaction: the shares moved -3.7% against the S&P 500 over the three sessions around the disclosure (9 Aug 2023 to 14 Aug 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- GPS investigator-sponsored trial topline data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-SLS-002010 · Corrections policy